- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Bolt Projects Holdings GAAP EPS of -$2.70, revenue of $0.37M | 1 | Seeking Alpha | ||
| 12.11. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | Bolt Projects announces prelim Q3 results and updates 2025 guidance | 1 | Seeking Alpha | ||
| 17.10. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.10. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.09. | Bolt Projects registers 20M shares for potential sale under $20M equity line | 2 | Seeking Alpha | ||
| 26.09. | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.09. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| BOLT PROJECTS Aktie jetzt für 0€ handeln | |||||
| 29.08. | Bolt Projects Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Bolt Projects files to sell 913,979 shares of common stock for holders | 1 | Seeking Alpha | ||
| 22.08. | Bolt Projects Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.08. | Bolt Projects to raise $4.25M in private placement | 5 | Seeking Alpha | ||
| 15.08. | Bolt Projects announces $4.25 million private placement | 1 | Investing.com | ||
| 14.08. | Aktie von Bolt Projects bricht nach Kapitalerhöhung mit hohem Abschlag ein | 2 | Investing.com Deutsch | ||
| 14.08. | Bolt Projects stock tumbles after discounted share offering | 12 | Investing.com | ||
| 14.08. | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | 697 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| 14.08. | Bolt Projects Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08. | Bolt Projects Holdings Stock Plunges Over 25% In Pre-Market Trading, Day After 557% Surge | 1 | Benzinga.com | ||
| 13.08. | Bolt Projects Stock Surges 38% on Strong Q2, $20M Funding; CEO: 'Demand For Vegan Silk Continues To Grow' | 15 | Benzinga.com | ||
| 12.08. | Bolt Projects Holdings, Inc. - 10-Q, Quarterly Report | 11 | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 2,067 | -1,29 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,012 | +10,09 % | SOL Global Investments Corp.: SOL Global Announces Share Consolidation | Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors... ► Artikel lesen | |
| TRINITY BIOTECH | 1,200 | +9,09 % | Trinity Biotech plc: Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation | DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,965 | +6,39 % | Fate Therapeutics, Inc.: Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs | ||
| ARCTURUS THERAPEUTICS | 7,200 | -3,36 % | Arcturus Raises $2.3M in Seed Funding | ||
| OVID THERAPEUTICS | 1,450 | +6,62 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| GENERATION BIO | 5,380 | +1,70 % | Generation Bio Co.: Generation Bio Announces CEO Transition | • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE,... ► Artikel lesen | |
| CABALETTA BIO | 2,495 | +0,60 % | Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update | Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient... ► Artikel lesen | |
| LONGEVERON | 0,650 | +9,63 % | Longeveron executives to speak at CVCT Forum on cell therapy trials | ||
| VOR BIOPHARMA | 10,700 | 0,00 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 66,74 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron | Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,88 | -7,87 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis | KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,530 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| ARCELLX | 70,84 | -4,37 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| VERA THERAPEUTICS | 44,660 | -0,82 % | Vera Therapeutics prices public offering to raise $261M at $42.50 a share |
BOLT PROJECTS HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,070 Euro und damit +4,02 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOLT PROJECTS HOLDINGS INC finden Sie auf Wallstreet Online.